Senior Solutions Architect

4DMT is seeking a Senior Solutions Architect to serve as a hands-on, business-facing technology leader and trusted IT partner supporting our G&A functions, including Procurement, Legal, Finance & Accounting, Human Resources, and Facilities. This role configures, optimizes, supports, and applies AI and automation to the G&A application portfolio, enabling compliant, scalable business processes that support 4DMT’s commercialization objectives.

A successful candidate will be a hands-on G&A Solutions Architect who personally combines enterprise application and integration build skills, AI innovation, stakeholder engagement, and governance discipline to enable scalable growth and commercial readiness., Business Partnership

• Serve as the day-to-day IT point of contact and trusted advisor to G&A stakeholders.
• Translate business requirements into practical, scalable, well-documented solutions.
• Run hands-on process improvement initiatives and maximize value from existing platforms.
• Drive user adoption through training, communication, and change management in partnership with the Business Process Owner (BPO).

Enterprise Applications Support and Solution

• Act as the functional and technical owner for applications used across the G&A ecosystem, with primary day-to-day responsibility for the Procurement, CLM, legal spend, and finance platforms in use; scope will shift as new G&A applications are implemented.
• Perform configuration, enhancements, UAT, security administration, and release/regression testing.
• Coordinate with outsourced remote MSP on day-to-day basis - ticket triage, backlog prioritization, SLA tracking, and escalation.
• Support the underlying business processes end-to-end from IT, technology and compliance standpoint, including contract lifecycle management, procurement, supplier data management, spend management, inventory management, and reporting
• Partner with stakeholders to evaluate and pilot new business technologies supporting future growth.

AI, Automation & Digital Transformation

• Identify and build opportunities to leverage AI, Copilot, and workflow automation.
• Implement automation solutions that measurably improve efficiency and user experience.
• Evaluate emerging technologies to modernize manual processes in partnership with business users, collaboratively with other IT team members.

Integration, Compliance & Governance

• Serve collaboratively as application SME and partner for the design, build and maintenance of enterprise integrations on modern integration platforms.
• Execute IT SOX, ITGC, audit, security, and SDLC/change management requirements, including evidence preparation and walkthrough support.
• Ensure solutions meet compliance, scalability, and operational standards while balancing efficiencies.

• Bachelor’s degree in Information Technology, Business Systems or equivalent

Experience:

• 8-12 years of hands-on enterprise business systems experience.
• Demonstrated delivery of efficiency gains using AI technologies and tools.
• Strong administration and implementation experience across G&A platforms, including:
• Procurement / P2P (Coupa)
• Contract lifecycle management (Ironclad or equivalent)
• Legal spend / matter management (Brightflag or equivalent)
• ERP - NetSuite or comparable (financials and inventory)
• Expert knowledge of procurement, sourcing, supply chain, inventory, supplier onboarding, legal operations, and related controls.
• Experience with SaaS integrations, APIs, middleware, and workflow automation platforms (such as Workato) - preferred, not required.
• MSP partnership and accountability for outsourced or offshore application support.
• Strong understanding of evidential SOX, ITGC, audit controls, and governance requirements.
• Experience supporting cross-functional business application integrations.
• Strong reporting, analytics, and process design capabilities.
• Familiarity with the Microsoft Azure framework, including Power Platform.
• Excellent stakeholder management, workload management and service delivery skills.
• Proven capability to work independently with full task ownership and minimal supervision.
• Consultative, results-oriented customer-focused mindset
• Strong analytical and problem-solving capabilities.
• Strong execution, follow-through, and prioritization skills across concurrent initiatives.
• High ownership, accountability, and attention to detail and documentation.
• Collaborative team player who thrives in a fast-paced semi-structured environment.
• Curiosity and passion for AI, automation, and continuous improvement.

Other Qualifications/Skills:

• Professional Certifications in Enterprise Platforms (Coupa, Ironclad, etc.) - preferred, not mandatory
• ITIL, TOGAF, or similar technology governance / architecture certification preferred.
• Hands-on business systems SME with Coupa and CLM expertise, plus working NetSuite and boundary-application knowledge.
• Experience supporting G&A processes in a commercial biopharma environment.
• Proven success delivering AI-enabled process improvements.
• Comfortable working directly with auditors, offshore/remote support teams, and business process owners.
• Able to balance assigned strategic projects, day-to-day support, and compliance responsibilities without losing hands-on depth and details.

Physical Requirements and Working Conditions:

• Physical Requirements - Sedentary work: Exerting up to 10 pounds of force occasionally and/or a negligible amount of force frequently or constantly to lift, carry, push, pull or otherwise move objects, including the human body. Sedentary work involves sitting most of the time. Jobs are sedentary if walking and standing are required only occasionally and all other sedentary criteria are met.
• Working Conditions - The worker is not substantially exposed to adverse environmental conditions (as in typical office or administrative work).

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery, 4DMT is a gene therapy company with a transformative discovery platform –Therapeutic Vector Evolution –that enables our “disease first” approach to product discovery and development, thereby allowing us to customize our AAV vectors to target specific tissue types associated with the underlying disease.

At 4DMT we are creating and developing optimized “biopharmaceutical grade” AAV vectors that will allow us uniquely to unlock the full potential of gene therapy. Our customized and proprietary AAV vectors are each designed, according to a 4DMT Target Vector Profile, to deliver genes to specific cells and tissues in the body to eradicate both rare and large market diseases.

While AAV gene therapy pioneers are making great strides with the first wave of products, hurdles still exist with the use of conventional vectors. The most commonly used AAV capsids (e.g., AAV2, 5, 8 and 9) were identified either 1) as contaminants in lab stocks of adenovirus, or 2) through monkey tissue processing. Therefore, these conventional vectors are not targeted specifically to any tissue in the body. This can lead to inefficient and non-specific delivery, thus requiring extremely high doses and potentially resulting in toxicities (including inflammation), high manufacturing burdens and suboptimal efficacy. In addition, suboptimal routes of delivery can be required for delivery to the right tissues (e.g., subretinal delivery to the retina). Finally, pre-existing neutralizing antibodies in many patients can limit efficacy, clinical trial enrollment and market sizes. 4DMT Innovation empowers us to create new and improved next generation AAV capsids to allow targeted delivery of our products by the optimal clinical route of administration.

At 4DMT we use our robust discovery platform, termed “Therapeutic Vector Evolution,” to create customized and proprietary gene delivery vehicles (novel AAV vectors) to deliver genes to specific tissues and cells in the body by the optimal route of administration. We use the power of evolution to create and refine these optimized vectors through genetic diversification and then natural selection in vivo.

4D Purpose Statement: Boldly Innovating to Unlock the Full Potential of Gene Therapy for Countless Patients

GUIDING PRINCIPLES

• Dare to Cure - Patients are waiting. Create big dreams for patients and take calculated risks to achieve them
• Break Boundaries - Question the status quo and innovate beyond conventional approaches
• Beyond Yourself - It’s about patients, their families, our team, our families. We strengthen each other.
• Prepare and Execute Relentlessly - Start with the end in mind, over-prepare and make contingency plans to your contingency plans

We invite all of you who share our passion and vision in creating the ultimate gene therapy products to cure genetic and rare diseases in children and adults. We seek the best people in the industry who identify with our mission and innovative results-driven approach. We offer an inspiring and collaborative environment that encourages individual contributions, recognizes performance in multiple ways, offers generous benefits and provides challenging opportunities for career development.